Clinical Trial Update: Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003) [Phase 1]

View source ↗

Summary

This update reports safety, pharmacokinetics, and pharmacodynamics data from Phase 1 testing of MK-6325 in hepatitis C virus infections. The study MK-6325-003 h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• MK-6325

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C | Phase 1 | Status: COMPLETED